Gilead Sciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Gilead Sciences sits in the top decile of US sponsors by registered trial count (#71 of 15,742 sponsors by registered trial count).
Gilead Sciences: 504 sponsored US clinical trials, 26 recruiting.
Gilead Sciences sponsors 504 registered US clinical trials on ClinicalTrials.gov, 26 of them currently recruiting, and 346 completed. 164 of these trials are in Phase 3-4 (later-stage) and 317 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV-1-infection, with 20 trials.
Top-decile sponsor footprint
Gilead Sciences ranks in the top decile of sponsors by registered trial count (#71 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
346 of 445 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
504 total, page 10 of 11
Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin
NCT00353587
Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.
NCT00298363
Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil
NCT00307489
Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.
NCT00298350
Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases.
NCT00263614
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
NCT00224445
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)
NCT00128492
A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B
NCT00116805
International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
NCT00112359
A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B
NCT00117676
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
NCT00104520
Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes
NCT00099788
Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients
NCT00106379
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
NCT00285428
Safety and Efficacy Study of 90Y-hPAM4 at Different Doses
NCT00597129
Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
NCT00113802
Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B
NCT00095121
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
NCT00208312
PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients
NCT00644761
ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
NCT00091598
ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
NCT00208299
Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects
NCT00112047
Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure
NCT00077948
Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection
NCT01055847
Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B
NCT00071201
Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
NCT00054834
Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension
NCT00046319
A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients
NCT00036634
Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs
NCT00016588
Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
NCT00041652
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer
NCT00040599
Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer
NCT00041639
A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection
NCT00002453
The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs
NCT00002379
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients
NCT00002234
The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients
NCT00002326
A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients
NCT00002426
A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS
NCT00002116
A Study of Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Been Treated With Anti-HIV Drugs
NCT00002206
An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS
NCT00002142
The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients
NCT00002346
The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
NCT00002437
Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations
NCT00002398
Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment
NCT00002419
The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients
NCT00002327
A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient
NCT00002184
Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients
NCT00002450
Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS
NCT00002181
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3
NCT00002161
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients
NCT00002128
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 134 |
| Phase 2 | 183 |
| Phase 3 | 150 |
| Phase 4 | 14 |
What is open in the Gilead Sciences pipeline
26 recruiting of 504 indexed (5% open); 346 completed (69%).
Phase mix: 164 late (III/IV) vs 317 early (I/II) (early-phase heavy).
Top condition: HIV-1-infection (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Gilead Sciences: open-pipeline peers nationwide
Peers matched on 504 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
Gilead Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 504 trials (± recruiting share)
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- Boehringer Ingelheim · 515 trials · 8% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Creighton University · 5% recruiting · 98 trials
- Almirall, S.A. · 5% recruiting · 19 trials
- Cordis US · 5% recruiting · 19 trials
- Defense and Veterans Center for Integrative Pain Management · 5% recruiting · 19 trials
Related
What to do with this Gilead Sciences page
504 registered trials is a research-attention snapshot, not an endorsement of Gilead Sciences or any single study.
- 26 of Gilead Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV-1-infection is the condition Gilead Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV-1-infection trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Gilead Sciences pipeline card: 504 registered trials from official public datasets.Report a data error.